MD Anderson and TOPPAN Holdings announce strategic alliance to co-develop organoid technology for evaluating cancer treatments
3D cell culture technology may allow researchers to rapidly test a variety of treatments directly on patient biopsies
Teams will evaluate technology as clinical tool for personalized cancer therapy
Collaboration will aim to obtain CAP/CLIA certification of organoid-based assay, followed by clinical studies in multiple indications
The University of Texas MD Anderson Cancer Center and TOPPAN Holdings today announced a strategic alliance...
MD Anderson ranked No. 1 in the nation for cancer care
Top ranking maintained for 11 years
National rankings in multiple subspecialties and high performing ratings for several procedures and...
MD Anderson announces 10th cohort of Andrew Sabin Family Fellows
HOUSTON ― The University of Texas MD Anderson Cancer Center today announced its 10th cohort of Andrew Sabin Family Fellows, comprised...
Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
87% of patients remained alive and 80% were disease free four years after treatment
Nearly all patients whose tumors responded to treatment before surgery remained disease-free after four years
Researchers found potential biomarkers that can highly predict which patients have better outcomes or are at high risk of recurrence...
New genetic marker linked to improved survival with immunotherapy in ovarian and other cancers
Ovarian clear cell carcinoma is difficult to treat, and treatment options are limited
Patients with specific PPP2R1A mutations...